Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 12, 2021

NIH says combination therapy effective in kids with leukaemia

In the trial, two-year overall survival rates were 99% and 100% for patients with standard- and high-risk APL, respectively.

The US National Institutes of Health (NIH) has reported that a combination therapy comprising all-trans retinoic acid and arsenic trioxide showed to be beneficial in a Phase III clinical trial to treat standard-risk and high-risk acute promyelocytic leukaemia (APL) in children.

All-trans retinoic acid is a metabolite of vitamin A.

Funded by NIH unit National Cancer Institute, the non-randomised, multi-institutional, cooperative group trial was carried out by the Children’s Oncology Group.

A total of 154 children aged between one and 22 years with recently detected standard-risk or high-risk APL were enrolled in the trial.

They were given oral all-trans retinoic acid in combination with an intravenous dose of arsenic trioxide for at least 28 days on a daily basis.

In the preliminary stage of the trial, participants with high-risk APL were also given four doses of anthracycline idarubicin.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Findings showed that almost all trial subjects survived for two years without disease relapse.

Standard chemotherapy was not needed for any of the children with standard-risk APL while those with the high-risk disease were given four doses of the chemotherapy drug idarubicin.

For standard-risk and high-risk APL patients, two-year overall survival rates respectively stood at 99% and 100%, with respective event-free survival rates reported to be 98% and 96%.

Furthermore, a child with standard-risk APL died early in the trial and one subject with standard-risk APL and two with high-risk APL relapsed.

Severe side effects were reported in less than 10% of the subjects during the initial stages of the trial with side effects such as high blood sugar, liver irritation and bleeding observed.

Trial lead investigator Matthew Kutny said: “As a paediatrician and an oncologist, I’ve had to have really difficult talks with families about what their child is facing and what type of therapy they’re going to have to go through to be cured.

“So being able to offer a therapy that is less intense and has fewer side effects, but at the same time has amazingly high survival rates, is a really good feeling.”

In a previous development, scientists from the NIH unit National Institute on Aging found that present and investigational therapies for cancer could potentially be repurposed to treat Alzheimer’s disease.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU